2. Cell Cycle/DNA Damage Apoptosis
  3. DNA/RNA Synthesis Apoptosis
  4. Kuanoniamine A

Kuanoniamine A is a pyridoacridine alkaloid and also an anticancer agent. Kuanoniamine A inhibits DNA synthesis, induces apoptosis, and regulates the cell cycle by reducing the proportion of cells in the G2/M phase. Kuanoniamine A inhibits the proliferation of human lymphocytes. Kuanoniamine A can be used in research related to breast cancer, glioma, non-small cell lung cancer, and melanoma.

For research use only. We do not sell to patients.

Kuanoniamine A

Kuanoniamine A Chemical Structure

CAS No. : 133401-10-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Kuanoniamine A Related Antibodies

Top Publications Citing Use of Products

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms
RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Kuanoniamine A is a pyridoacridine alkaloid and also an anticancer agent. Kuanoniamine A inhibits DNA synthesis, induces apoptosis, and regulates the cell cycle by reducing the proportion of cells in the G2/M phase. Kuanoniamine A inhibits the proliferation of human lymphocytes. Kuanoniamine A can be used in research related to breast cancer, glioma, non-small cell lung cancer, and melanoma[1].

In Vitro

Kuanoniamine A (48 h) potently inhibits the growth of MCF-7, MDA-MB-231, NCI-H460, SF-268, UACC-62, and MRC-5 cells with GI50 values ranging from 0.12 to 4.67 μM after 48 h of continuous exposure[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) potently inhibits DNA synthesis in MCF-7 cells, with a concentration-dependent effect that reduces thymidine incorporation by over 60% at 0.08 μM across 6, 12, 24, and 48 h exposure times[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces MCF-7 cell viability in a time-dependent manner, decreasing viability to 70% at 0.04 μM after 6 h exposure, with more severe reductions after 24 and 48 h[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces cellular protein content in MCF-7 cells in a time-dependent manner, with effects mirroring its impact on cell viability measured by the MTT assay[1].
Kuanoniamine A (0.34 μM; 24 h) reduces the proportion of MCF-7 cells in G2/M phase, accumulates cells in G1 phase, and decreases the S phase fraction relative to untreated control cells[1].
Kuanoniamine A (0.5-1.0 μM; 24 h) increases the number of apoptotic MCF-7 cells relative to untreated control cells[1].
Kuanoniamine A (0.5-2.5 μM; 24 h) reduces MCF-7 cell viability to ≥70% at 0.5 and 1.0 μM after 24 h, while 2.5 μM drastically reduces viability to 35.7%[1].
Kuanoniamine A (0.12-86.51 μM; 96 h) potently inhibits PHA-induced proliferation of human lymphocytes with an IC50 of 1.50 μM after 96 h of continuous exposure[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Kuanoniamine A Related Antibodies

Cell Cycle Analysis[1]

Cell Line: MCF-7
Concentration: 0.34 μM
Incubation Time: 24 h
Result: Caused an extensive reduction in the fraction of cells in G2/M phase (5.71% vs.
12.17% in control), a corresponding accumulation of cells in G1 phase (81.41% vs.
70.04% in control), and a reduction in the S phase fraction (12.88% vs.
17.79% in control).

Apoptosis Analysis[1]

Cell Line: MCF-7
Concentration: 0.5 and 1.0 μM
Incubation Time: 24 h
Result: Increased the number of apoptotic cells; 0.5 μM treatment resulted in 6.19% apoptotic cells, and 1.0 μM treatment resulted in 7.2% apoptotic cells, compared to 1.41% in untreated control cells.

Cell Viability Assay[1]

Cell Line: MCF-7
Concentration: 0.5, 1 and 2.5 μM
Incubation Time: 24 h
Result: Moderately reduced viability at 0.5 and 1.0 μM (≥70% viable cells), while 2.5 μM caused a drastic decrease in viability to 35.7%.
Molecular Weight

289.31

Formula

C16H7N3OS
CAS No.
SMILES

O=C1C2=NC=3C=CC=CC3C=4C=CN=C(C=5N=CSC15)C24
Structure Classification
Initial Source

Oceanapia sagittaria
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Kuanoniamine A Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Kuanoniamine A133401-10-2DNA/RNA SynthesisApoptosiscell cycleOceanapia sagittarianon small cell lung cancergliomabreast carcinomahuman non-tumour cell linesapoptosisDNA synthesishuman tumour cell lineshuman lymphocytesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Kuanoniamine A
Cat. No.:
HY-118713
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.